Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11530236 CD73 inhibitors

Patent 11530236 was granted and assigned to ORIC Pharmaceuticals on December, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

ORIC Pharmaceuticals

0

Current Assignee

ORIC Pharmaceuticals

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Brian R. Blank0

Qiuping Ye0

Tatiana Zavorotinskaya0

Valeria R. Fantin0

Xiaohui Du0

Yosup Rew0

Chien-Hung Yeh0

Daqing Sun0

...

Date of Patent

December 20, 2022

0

Patent Application Number

170838710

Date Filed

October 29, 2020

0

Patent Citations

US Patent 10239912 Modulators of 5′-nucleotidase, ecto and the use thereof

US Patent 11028120 CD73 inhibitors

US Patent 11129841 CD73 inhibitors

US Patent 11130778 CD73 inhibitors

0

Patent Citations Received

US Patent 12018043 CD73 inhibitors

0

Patent Primary Examiner

0

CPC Code

0

0

Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11530236 CD73 inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.